Max Macaluso, Ph.D. Articles

•   RSS Feed
• View Profile

Last 50 articles...

• Unclear Future for Merck's Insomnia Drug
• Regeneron and Sanofi: An Unstoppable Biotech Duo?
• What's Behind Medtronic's 5% Pop?
• Will the FDA Approve Merck's Insomnia Drug?
• AbbVie's New Crohn's Disease Drug Candidate
• Is Keryx Biopharmaceuticals Burning Too Much Cash?
• AbbVie Investors, Watch This Management Change
• The New Generic-Drug Battle Front
• 3 Most Important Upcoming FDA Decisions of 2013
• Sanofi and Regeneron's Latest Partnership
• What Does This Failure Mean for Eli Lilly Investors?
• 4 Technologies That Can Help Track Weight Loss
• This Week in Health Care
• Why NPS Pharmaceuticals Is Up After Earnings
• 3 Key Takeaways From Keryx's Earnings Report
• Is Orexigen Therapeutics Burning Too Much Cash?
• This Week in Health Care
• Hot Off the Press: Arena Pharmaceuticals’ First Quarter Results
• Teva's 3 Biggest Challenges
• Is a Pharmaceutical Company the Same as a Biotech?
• 1 Simple Way to Be a Better Investor
• 2 Upcoming Catalysts for Amarin
• Why This Obesity Drugmaker's Prescription Data Tells Only Half the Story
• This Week in Health Care
• Obesity and Weight Management: How Much Weight Loss is Actually Necessary?
• 2 Things Regeneron Investors Need to Watch
• How Allergy Season Taught Me an Important Investing Lesson
• This Week in Health Care
• Want to Retire Soon? Don't Invest in This Industry!
• The Hidden Industry That's Saving Your Life
• The Most Surprising FDA Decisions of 2013
• The Weaknesses in Sanofi's Diabetes Franchise
• The Role Medication Plays in Treating Obesity
• How Doctors Actually Diagnose Obesity
• How the "BRAIN Initiative" Can Help Big Pharma
• This Week in Health Care
• Health Care's Elite Eight Stocks: Johnson & Johnson vs. Novartis
• Should Novartis Investors Worry About This Supreme Court Ruling?
• Should Merck Investors Worry About This Supreme Court Decision?
• Market Madness Showdown: AstraZeneca vs. Merck
• Market Madness Showdown: Sanofi vs. Eli Lilly
• Market Madness Showdown: AbbVie vs. GlaxoSmithKline
• Market Madness Showdown: Abbott vs. Novo Nordisk
• Is IBM's Watson Really a Big Deal?
• Johnson & Johnson Waits for FDA Ruling on new Diabetes Drug
• Was Obagi Medical the Right Acquisition for Valeant?
• Will This Upcoming FDA Decision Give Allergan a Headache?
• Is This Obesity-Drug Maker in Trouble?
• FDA Deliberates on an Emerging Type 2 Diabetes Drug Class
• 5 Hidden Causes of Obesity